Benzinga
Benzinga
Benzinga
mercredi, septembre 30

Capricor Therapeutics Inc

CAPRNASDAQ
Trade with Public
Trade with Public
$9.47
0.9010.5%
À la clôture: Sep 30, 5:00 PM EST
$9.43
-0.0354-0.37%
Après les heures: 6:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Capricor Therapeutics Financials

Capricor Therapeutics (CAPR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
Vandana Singh

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
Mohd Haider

PRO
Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over losses of $(0.57) per
Benzinga Newsdesk

PRO
Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Capricor Therapeutics Believes That, Based On The Current Operating Plan And Financial Resources, Its Available Cash, Cash Equivalents And Marketable Securities Will Be Sufficient To Cover Anticipated Expenses And Capital Requirements Through 2027

Expectation Excludes Any Additional Potential Milestone Payments Under The Commercialization And Distribution Agreements With Nippon Shinyaku, As Well As Any Strategic Use Of Capital Not Currently In The Company's Base
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved